29959802|t|Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects.
29959802|a|AIMS: SD-1077, a selectively deuterated precursor of dopamine (DA) structurally related to L-3,4-dihydroxyphenylalanine (L-DOPA), is under development for treatment of motor symptoms of Parkinson's disease. Preclinical models have shown slower metabolism of central deuterated DA. The present study investigated the peripheral pharmacokinetics (PK), metabolism and safety of SD-1077. METHODS: Plasma and urine PK of drug and metabolites and safety after a single oral 150 mg SD-1077 dose were compared to 150 mg L-DOPA, each in combination with 37.5 mg carbidopa (CD) in a double-blind, two-period, crossover study in healthy volunteers (n = 16). RESULTS: Geometric least squares mean ratios (GMRs) and 90% confidence intervals (90% CI) of SD-1077 vs. L-DOPA for Cmax , AUC0-t , and AUC0-inf were 88.4 (75.9-103.1), 89.5 (84.1-95.3), and 89.6 (84.2-95.4), respectively. Systemic exposure to DA was significantly higher after SD-1077/CD compared to that after L-DOPA/CD, with GMRs (90% CI) of 1.8 (1.45-2.24; P = 0.0005) and 2.06 (1.68-2.52; P < 0.0001) for Cmax and AUC0-t and a concomitant reduction in the ratio of 3,4-dihydroxyphenylacetic acid/DA confirming slower metabolic breakdown of DA by monoamine oxidase (MAO). There were increases in systemic exposures to metabolites of catechol O-methyltransferase (COMT) reaction, 3-methoxytyramine (3-MT) and 3-O-methyldopa (3-OMD) with GMRs (90% CI) for SD-1077/CD to L-DOPA/CD for 3-MT exposure of 1.33 (1.14-1.56; P = 0.0077) and 1.66 (1.42-1.93; P < 0.0001) for Cmax and AUC0-t , respectively and GMRs (90% CI) for 3-OMD of 1.19 (1.15, 1.23; P < 0.0001) and 1.31 (1.27, 1.36; P < 0.0001) for Cmax and AUC0-t . SD-1077/CD exhibited comparable tolerability and safety to L-DOPA/CD. CONCLUSIONS: SD-1077/CD demonstrated the potential to prolong exposure to central DA at comparable peripheral PK and safety to the reference L-DOPA/CD combination. A single dose of SD-1077 is safe for further clinical development in Parkinson's disease patients.
29959802	54	60	L-DOPA	Chemical	MESH:D007980
29959802	62	70	SD-1077)	Chemical	-
29959802	71	80	carbidopa	Chemical	MESH:D002230
29959802	93	99	L-DOPA	Chemical	MESH:D007980
29959802	100	109	carbidopa	Chemical	MESH:D002230
29959802	179	186	SD-1077	Chemical	-
29959802	226	234	dopamine	Chemical	MESH:D004298
29959802	236	238	DA	Chemical	MESH:D004298
29959802	264	292	L-3,4-dihydroxyphenylalanine	Chemical	MESH:D007980
29959802	294	300	L-DOPA	Chemical	MESH:D007980
29959802	359	378	Parkinson's disease	Disease	MESH:D010300
29959802	450	452	DA	Chemical	MESH:D004298
29959802	548	555	SD-1077	Chemical	-
29959802	648	655	SD-1077	Chemical	-
29959802	685	691	L-DOPA	Chemical	MESH:D007980
29959802	726	735	carbidopa	Chemical	MESH:D002230
29959802	737	739	CD	Chemical	MESH:D002230
29959802	913	920	SD-1077	Chemical	-
29959802	925	931	L-DOPA	Chemical	MESH:D007980
29959802	1064	1066	DA	Chemical	MESH:D004298
29959802	1098	1105	SD-1077	Chemical	-
29959802	1106	1108	CD	Chemical	MESH:D002230
29959802	1132	1138	L-DOPA	Chemical	MESH:D007980
29959802	1139	1141	CD	Chemical	MESH:D002230
29959802	1290	1320	3,4-dihydroxyphenylacetic acid	Chemical	MESH:D015102
29959802	1321	1323	DA	Chemical	MESH:D004298
29959802	1365	1367	DA	Chemical	MESH:D004298
29959802	1457	1485	catechol O-methyltransferase	Gene	1312
29959802	1487	1491	COMT	Gene	1312
29959802	1503	1520	3-methoxytyramine	Chemical	MESH:C001746
29959802	1522	1526	3-MT	Chemical	MESH:C001746
29959802	1532	1546	3-O-methyldopa	Chemical	MESH:C008404
29959802	1548	1553	3-OMD	Chemical	MESH:C008404
29959802	1578	1585	SD-1077	Chemical	-
29959802	1586	1588	CD	Chemical	MESH:D002230
29959802	1592	1598	L-DOPA	Chemical	MESH:D007980
29959802	1599	1601	CD	Chemical	MESH:D002230
29959802	1606	1610	3-MT	Chemical	MESH:C001746
29959802	1742	1747	3-OMD	Chemical	MESH:C008404
29959802	1837	1844	SD-1077	Chemical	-
29959802	1845	1847	CD	Chemical	MESH:D002230
29959802	1896	1902	L-DOPA	Chemical	MESH:D007980
29959802	1903	1905	CD	Chemical	MESH:D002230
29959802	1920	1928	SD-1077/	Chemical	-
29959802	1928	1930	CD	Chemical	MESH:D002230
29959802	1989	1991	DA	Chemical	MESH:D004298
29959802	2048	2054	L-DOPA	Chemical	MESH:D007980
29959802	2055	2057	CD	Chemical	MESH:D002230
29959802	2088	2095	SD-1077	Chemical	-
29959802	2140	2159	Parkinson's disease	Disease	MESH:D010300
29959802	2160	2168	patients	Species	9606
29959802	Comparison	MESH:D004298	MESH:D007980
29959802	Comparison	MESH:C008404	MESH:D002230
29959802	Cotreatment	MESH:D002230	MESH:D004298
29959802	Negative_Correlation	MESH:D004298	MESH:D010300
29959802	Comparison	MESH:C001746	MESH:D002230
29959802	Negative_Correlation	MESH:D007980	MESH:D010300
29959802	Cotreatment	MESH:D002230	MESH:D007980
29959802	Cotreatment	MESH:D002230	MESH:D015102

